Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention

被引:0
作者
Tatiana R. Perry
Michelle L. Roberts
Bipin Sunkara
Ragasnehith Maddula
Tyson McLeish
Jose Gomez
Julliette Lucas
David Rayan
Sahishnu Patel
Mingyu Liang
Zeljko J. Bosnjak
Sherry-Ann Brown
机构
[1] Medical College of Wisconsin,PhD Program in Physiology, Graduate School of Biomedical Sciences
[2] Medical College of Wisconsin,PhD Program in Basic and Translational Science, Clinical and Translational Science Institute
[3] Medical College of Wisconsin,Department of Physiology, Center of Systems Molecular Medicine
[4] Medical College of Wisconsin,Department of Medicine
[5] Medical College of Wisconsin,Cardio
[6] Medical College of Wisconsin,Oncology Program, Division of Cardiovascular Medicine
来源
Current Oncology Reports | 2021年 / 23卷
关键词
Cardio-oncology; Cardiovascular toxicity; hiPSCs; Precision medicine; Risk stratification; Prevention;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 808 条
[1]  
Han X(2017)Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy NPJ Precis Oncol 1 31-1770
[2]  
Zhou Y(2018)Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it? Eur Heart J 40 1764-731
[3]  
Liu W(2015)Systems biology approaches to adverse drug effects: the example of cardio-oncology Nat Rev Clin Oncol 12 718-80
[4]  
Stack JP(2017)Cardiovascular toxicities of small molecule tyrosine kinase inhibitors: an opportunity for systems-based approaches Clin Pharmacol Ther 101 65-e602
[5]  
Moslehi J(2019)Preventive cardio-oncology: the time has come Front Cardiovasc Med 6 187-774
[6]  
Sayed N(2019)Cardio-oncology: vascular and metabolic perspectives: a scientific statement from the American Heart Association Circulation. 139 e579-e66
[7]  
Wu JC(2018)Cardiac toxicities in the era of precision medicine: underlying risk factors, targeted therapies, and cardiac biomarkers Am Soc Clin Oncol Educ Book 38 764-734
[8]  
Brown SA(2018)Cardiovascular disease and breast cancer: where these entities intersect: a scientific statement from the American Heart Association Circulation. 137 e30-1467
[9]  
Sandhu N(2018)Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger Circulation. 138 727-756
[10]  
Herrmann J(2016)Cardiovascular toxic effects of targeted cancer therapies N Engl J Med 375 1457-673